Table 1. Baseline and treatment characteristics of 39 patients with non-small cell lung cancer.
| Category | Item | Number |
| Age (years; median, range) | 66 (45-87) | |
| Duration (days; median, range) | First TKI | 79 (10-639) |
| All TKI | 125 (10-899) | |
| Gender | Men | 18 |
| Women | 21 | |
| Active mutation | Exon 19 | 19 |
| Exon 21 | 17 | |
| Exon 18 | 3 | |
| Stage | IIIB | 8 |
| IV | 23 | |
| postoperative recurrence | 8 | |
| Histopathology | Adenocarcinoma | 36 |
| Adeno-squamous carcinoma | 1 | |
| Squamous cell carcinoma | 2 | |
| First-line chemotherapy | Cytotoxic | 26 |
| TKI | 13 | |
| Response to first chemotherapy | PR | 14 |
| SD | 9 | |
| PD | 5 | |
| (TKI alone) | (11) | |
| First TKI | Gefitinib | 30 |
| Erlotinib | 9 | |
| First TKI response | PR | 19 |
| PD | 13 | |
| NE | 7 | |
| Re-challenge TKI | Yes | 15 |
| No | 24 |
TKI, tyrosine kinase inhibitor; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated.